
SOTS 2nd Hour: Nvidia Hits $4T, The Battle of the Kevins, Exclusive: Snap CEO 7/9/25
Squawk on the Street
00:00
Novo Nordisk's Patent Lapse Opens New Market Opportunities
This chapter examines a critical patent oversight by Novo Nordisk that jeopardizes exclusivity for their weight loss drugs, Ozempic and Wagovi, in Canada. The failure to pay a $450 licensing fee in time could lead to major competition from generic versions in a rapidly expanding market.
Transcript
Play full episode